Observation on the effect of montelukast combined with alpha-interferon and budesonide in the treatment of children with upper respiratory tract infection
10.3760/cma.j.issn.1008-6706.2013.18.008
- VernacularTitle:孟鲁司特联合α-干扰素、布地奈德治疗儿童上呼吸道感染的疗效观察
- Author:
Ping ZHOU
- Publication Type:Journal Article
- Keywords:
Respiratory tract infections;
Montelukast;
Interferon;
Treatment outcome
- From:
Chinese Journal of Primary Medicine and Pharmacy
2013;20(18):2740-2742
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficiency of montelukast combined with alpha-interferon and budesonide in the treatment of children with upper respiratory tract infection.Methods According to the digital table,120 children with upper respiratory tract infection were randomly divided into the control group and the observation group,each group 60 cases.The control group was given anti-infection treatment,rehydration,controlling cough and other conventional treatment,and the observation group on the basis of the control group was given montelukast combined alpha-interferon,budesonide.The treatment course was 5d.The time of fever,coughing and wheezing disappeared and efficacy were compared between the two groups.Results The effective rate in the observation group was 80.0％,which was significantly better than that of the control group(53.0％) (χ2 =27.87,P ＜ 0.01).The total effective rate of the observation group was 95.0％,which had no significant difference with that of the control group (90.0％)(χ2 =1.92,P ＞ 0.05).The heating time and the cough last time of the observation group was (1.74 ± 0.75) h,(2.92 ± 0.56) h,respectively,which were significantly shorter than those of the control group [(2.82 ± 0.64) h,(4.13 ± 0.54)h] (t =3.142,3.143,all P ＜ 0.01).Conclusion Montelukast combined with alpha-interferon and budesonide in the treatment of children with upper respiratory tract infection is effective and safety,which has little adverse reactions and is worthy of promotion and clinical application.
